公开(公告)号：US10071130B2

公开(公告)日：2018-09-11

申请号：US15103187

申请日：2014-12-12

Applicant: The University of Chicago

Inventor： Suzanne D. Conzen

IPC: A61K31/535 ,  A61K38/05 ,  A61K45/06 ,  A61K31/7048 ,  A61K31/337 ,  A61K31/4196 ,  A61K31/5377 ,  A61N5/10 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: A61K38/05 ,  A61K31/337 ,  A61K31/4196 ,  A61K31/5377 ,  A61K31/7048 ,  A61K45/06 ,  A61N5/10 ,  C12Q1/6886 ,  G01N33/57415 ,  G01N33/57434 ,  G01N33/57492 ,  G01N2333/705 ,  A61K2300/00

Abstract: Embodiments of the invention are directed to methods of treating cancer cells, particularly breast cancer cells, such as chemo-resistant cells, with an Hsp90 inhibitor and an anticancer agent or compound such as chemotherapy.

公开(公告)号：US09801893B2

公开(公告)日：2017-10-31

申请号：US15013660

申请日：2016-02-02

Applicant: The University of Chicago

Inventor： Russell Z. Szmulewitz ,  Suzanne D. Conzen

IPC: A61K31/00 ,  A61K45/00 ,  A61K31/567 ,  A61K31/4166 ,  A61K31/437 ,  A61K31/569 ,  A61K31/573 ,  A61K45/06 ,  A61N5/10

CPC classification number: A61K31/567 ,  A61K31/4166 ,  A61K31/437 ,  A61K31/569 ,  A61K31/573 ,  A61K45/06 ,  A61N5/10 ,  A61K2300/00

Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.

公开(公告)号：US12280066B2

公开(公告)日：2025-04-22

申请号：US18541675

申请日：2023-12-15

Applicant: The University of Chicago

Inventor： Deng Pan ,  Masha Kocherginsky ,  Suzanne D. Conzen

IPC: A61K31/575 ,  A61J1/00 ,  A61K31/282 ,  A61K31/337 ,  A61K31/357 ,  A61K31/4745 ,  A61K31/567 ,  A61K31/58 ,  A61K31/7068 ,  A61K33/243 ,  A61K39/395 ,  A61K45/06 ,  A61N5/00

Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

公开(公告)号：US20200330482A1

公开(公告)日：2020-10-22

申请号：US16913916

申请日：2020-06-26

Applicant: The University of Chicago

Inventor： Russell Z. Szmulewitz ,  Suzanne D. Conzen

IPC: A61K31/567 ,  A61K31/4166 ,  A61K31/437 ,  A61K31/569 ,  A61K31/573 ,  A61K45/06 ,  A61N5/10

Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.

公开(公告)号：US20160151388A1

公开(公告)日：2016-06-02

申请号：US15013660

申请日：2016-02-02

Applicant: The University of Chicago

Inventor： Russell Z. Szmulewitz ,  Suzanne D. Conzen

IPC: A61K31/567 ,  A61N5/10 ,  A61K31/4166

CPC classification number: A61K31/567 ,  A61K31/4166 ,  A61K31/437 ,  A61K31/569 ,  A61K31/573 ,  A61K45/06 ,  A61N5/10 ,  A61K2300/00

Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.

公开(公告)号：US11883417B2

公开(公告)日：2024-01-30

申请号：US17577882

申请日：2022-01-18

Applicant: The University of Chicago

Inventor： Deng Pan ,  Masha Kocherginsky ,  Suzanne D. Conzen

IPC: A61K31/575 ,  A61K45/06 ,  A61K33/243 ,  A61K31/282 ,  A61K31/337 ,  A61K31/357 ,  A61K31/4745 ,  A61K31/7068 ,  A61K39/395 ,  A61N5/00 ,  A61J1/00 ,  A61K31/567 ,  A61K31/58

CPC classification number: A61K31/575 ,  A61J1/00 ,  A61K31/282 ,  A61K31/337 ,  A61K31/357 ,  A61K31/4745 ,  A61K31/567 ,  A61K31/58 ,  A61K31/7068 ,  A61K33/243 ,  A61K39/3955 ,  A61K45/06 ,  A61N5/00 ,  A61K31/575 ,  A61K2300/00

Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

公开(公告)号：US11234990B2

公开(公告)日：2022-02-01

申请号：US16596342

申请日：2019-10-08

Applicant: The University of Chicago

Inventor： Deng Pan ,  Masha Kocherginsky ,  Suzanne D. Conzen

IPC: A61K31/575 ,  A61K45/06 ,  A61K33/243 ,  A61K31/282 ,  A61K31/337 ,  A61K31/357 ,  A61K31/4745 ,  A61K31/7068 ,  A61K39/395 ,  A61N5/00 ,  A61J1/00 ,  A61K31/567 ,  A61K31/58

Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

公开(公告)号：US10729699B2

公开(公告)日：2020-08-04

申请号：US16374157

申请日：2019-04-03

Applicant: The University of Chicago

Inventor： Russell Z. Szmulewitz ,  Suzanne D. Conzen

IPC: A61K31/567 ,  A61K31/4166 ,  A61K31/437 ,  A61K31/569 ,  A61K31/573 ,  A61K45/06 ,  A61N5/10

Abstract: Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.

公开(公告)号：US09289436B2

公开(公告)日：2016-03-22

申请号：US14380606

申请日：2013-02-21

Applicant: The University of Chicago

Inventor： Russell Z. Szmulewitz ,  Suzanne D. Conzen

IPC: A61K31/00 ,  A61K45/00 ,  A61K31/567 ,  A61K31/4166 ,  A61K31/437 ,  A61K31/569 ,  A61K31/573 ,  A61K45/06

CPC classification number: A61K31/567 ,  A61K31/4166 ,  A61K31/437 ,  A61K31/569 ,  A61K31/573 ,  A61K45/06 ,  A61N5/10 ,  A61K2300/00

Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.

Abstract translation: 方法涉及用具有糖皮质激素受体拮抗剂的前列腺癌，特别是那些具有去钙抗性前列腺癌的受试者的治疗。 前列腺癌可以是例如通过增加糖皮质激素受体表达和/或活性而变得对雄激素剥夺治疗具有抗性的前列腺癌。

公开(公告)号：US20140186367A1

公开(公告)日：2014-07-03

申请号：US14172051

申请日：2014-02-04

Applicant: The University of Chicago

Inventor： Deng PAN ,  Masha Kocherginsky ,  Suzanne D. Conzen

IPC: A61K31/575 ,  A61K45/06 ,  A61K31/282 ,  A61N5/00 ,  A61K31/357 ,  A61K39/395 ,  A61K31/4745 ,  A61K31/337 ,  A61K31/7068 ,  A61K33/24

CPC classification number: A61K31/575 ,  A61J1/00 ,  A61K31/282 ,  A61K31/337 ,  A61K31/357 ,  A61K31/4745 ,  A61K31/567 ,  A61K31/58 ,  A61K31/7068 ,  A61K33/24 ,  A61K39/3955 ,  A61K45/06 ,  A61N5/00 ,  A61K2300/00

Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

Abstract translation: 本发明的实施方案涉及通过评估肿瘤细胞中糖皮质激素受体的活性来确定乳腺癌患者的预后的方法。 其他实施方案包括用糖皮质激素受体拮抗剂和抗癌剂或化合物治疗乳腺癌细胞，特别是化学抗性细胞的方法。